Abstract:Otomycosis is a fungal infection of the outer ear, which may be treated with topical antifungal medications. There are many types, with compounds belonging to the azole group ('azoles') being among the most widely used. To evaluate the benefits and harms of topical azole treatments for otomycosis. The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The search date was 11 November 2020. We included randomised controlled trials (RCTs) in adults and children with otomycosis comparing any topical azole antifungal with: placebo, no treatment, another type of topical azole or the same type of azole but applied in different forms. A minimum follow‐up of two weeks was required. We used standard Cochrane methods. Our primary outcomes were: 1) clinical resolution as measured by the proportion of participants with complete resolution at between two and four weeks after treatment (however defined by the authors of the studies) and 2) significant adverse events. Secondary outcomes were 3) mycological resolution and 4) other less serious adverse effects. We used GRADE to assess the certainty of evidence for each outcome. We included four studies with 559 participants from Spain, Mexico and India. Three studies included children and adults; one included only adults. The duration of symptoms was not always explicitly stated. Mycological resolution results were only reported in one study. The studies assessed two comparisons: one type of topical azole versus another and the same azole but administered in different forms (cream versus solution). A. Topical azoles versus placebo None of the studies assessed this comparison. B. Topical azoles versus no treatment None of the studies assessed this comparison. C. One type of topical azole versus another type of topical azole i) Clotrimazole versus other types of azoles (eberconazole, fluconazole, miconazole) Three studies examined clotrimazole versus other types of azoles. The evidence is very uncertain about the difference between clotrimazole and other types of azole in achieving complete clinical resolution at four weeks (risk ratio (RR) 0.80, 95% confidence interval (CI) 0.59 to 1.07; 3 studies; 439 participants; very low‐certainty evidence). The anticipated absolute effects are 668 per 1000 for clotrimazole versus 835 per 1000 for other azoles. One study planned a safety analysis and reported no significant adverse events in either group. The evidence is therefore very uncertain about any differences between clotrimazole and other types of azole (no events in either group; 1 study; 174 participants; very low‐certainty evidence). Clotrimazole may result in little or no difference in mycological resolution at two weeks follow‐up (RR 1.01, 95% CI 0.96 to 1.06; 1 study; 174 participants; low‐certainty evidence) or in other (less serious) adverse events at two weeks follow‐up (36 per 1000, compared to 45 per 1000, RR 0.79, 95% CI 0.18 to 3.41; 1 study; 174 participants; very low‐certainty evidence). ii) Bifonazole cream versus bifonazole solution One study compared bifonazole 1% cream with solution. Bifonazole cream may have little or no effect on clinical resolution at two weeks follow‐up when compared to solution, but the evidence is very uncertain (RR 1.07, 95% CI 0.73 to 1.57; 1 study; 40 ears; very low‐certainty evidence). Bifonazole cream may achieve less mycological resolution compared to solution at two weeks after the end of therapy, but the evidence for this is also very uncertain (RR 0.53, 95% CI 0.29 to 0.96; 1 study; 40 ears; very low‐certainty evidence). Five out of 35 patients sustained severe itching and burning from the bifonazole solution but none with the bifonazole cream (very low‐certainty evidence). We found no studies that evaluated topical azoles compared to placebo or no treatment. The evidence is very uncertain about the effect of clotrimazole on clinical resolution of otomycosis, on significant adverse events or other (non‐serious) adverse events when compared with other topical azoles (eberconazole, fluconazole, miconazole). There may be little or no difference between clotrimazole and other azoles in terms of mycological resolution. It may be difficult to generalise these results because the range of ethnic backgrounds of the participants in the studies is limited. Key messages Due to weak evidence, we do not know if: ‐ azoles taken as a cream or drops are better than no treatment or a placebo (dummy) treatment; ‐ some azoles are better at ending infections than others. There is a need for well‐conducted studies that investigate the risks and benefits of these treatments for otomycosis. What is otomycosis? Otomycosis is an ear in -Abstract Truncated-

Efficacy and Safety of Terbinafine Hydrochloride Spray and 3% Boric Acid Alcohol Ear Drops in Otomycosis

Terbinafine versus itraconazole for treatment of dermatophyte onychomycosis: a meta-analysis

A Comparison Of Triamcinolone Acetonide Econazole Cream And Nystatin Suspension In Treatment Of Otomycosis

Eradicating Otomycosis with Terbinafine Solution: Basic and Clinical Investigation

Efficacy of 3% diquafosol combined with azelastine hydrochloride in allergic conjunctivitis patients with dry eye

Topical azole treatments for otomycosis.

Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis

Otomycosis in Shanghai: Aetiology, Clinical Features and Therapy

Identification of the Fungal Community in Otomycosis by Internal Transcribed Spacer Sequencing

Comparison of acidifying agents and clotrimazole for treatment of otomycosis: a comprehensive one-way mini-review

Administration of 1% topical voriconazole drops was effective and safe in the treatment of refractory otomycosis without tympanic membrane perforation

Topical Antibiotic-Induced Otomycosis - a Systematic Review of Aetiology and Risk Factors

Efficacy of combination of acetic acid and ciprofloxacin eardrops versus only ciprofloxacin eardrops in achieving dry ears in chronic suppurative otitis media

Combination Treatment of Oral Terbinafine with Topical Terbinafine and 10% Urea Ointment in Hyperkeratotic Type Tinea Pedis.

Comparative efficacy of 1% terbinafine hydrochloride cream and 1% ciclopirox olamine cream alone and in combination for the treatment of dermatophytosis

Study on the microbial diversity of ear canal secretions from patients with otomycosis

Comparing the Therapy of Otomycosis Using Clotrimazole with Iodine Tincture: A Clinical Trial

In Vitro Combination of Terbinafine with Ketoconazole Against Aspergillus Species with Terbinafine High MIC Values Isolated From Otomycosis

COMPARATIVE STUDY OF EFFICACY OF ORAL TERBINAFINE ALONE AND ORAL TERBINAFINE WITH TOPICAL 8% CICLOPIROX OLAMINE IN ONYCHOMYCOSIS

Efficacy of topical trichloroacetic acid 100% either alone or combined with topical tioconazole 28% versus systemic itraconazole in the treatment of onychomycosis

The Clinical Effect of XTR Combined with Terbinafine in 46 Patients with Toenail Onychomycosis